NEW YORK (GenomeWeb News) – IntegraGen and French oncology center Gustave Roussy today announced the creation of a high-throughput, large-scale sequencing platform that is anticipated to direct patients enrolled in personalized medicine studies to the most appropriate therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.